FIELD: medicine, pharmaceutics.
SUBSTANCE: the suggested pharmaceutical composition includes formoterol and its pharmaceutically acceptable salt and flucticason propionate at their weight ratio being, correspondingly, 1 : 5 to 1 : 50. Combined application of flucticason propionate and formoterol fumarate provides synergistic therapeutic action that enables to decrease the dosage of flucticason propionate for achieving concrete antiphlogistic action that leads to possible unfavorable side effects.
EFFECT: higher efficiency of application.
10 cl, 216 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MEDICINAL AGENT AND PHARMACEUTICAL SET DESIGNATED FOR ASTHMA TREATMENT | 2000 |
|
RU2270670C2 |
| COMPOSITIONS COMPRISING FORMOTEROL AND THIOTROPIUM SALT | 2000 |
|
RU2238085C2 |
| PHARMACEUTICAL COMPOSITION | 2011 |
|
RU2642624C2 |
| COMBINATION AND PHARMACEUTICAL PREPARATION FOR TREATING INFLAMMATORY AND OBSTRUCTIVE RESPIRATORY DISEASES | 2005 |
|
RU2438660C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ARFORMOTEROL AND FLUTICASONE FUROATE | 2013 |
|
RU2678992C2 |
| PHARMACEUTICAL COMPOSITIONS | 2011 |
|
RU2568882C2 |
| AEROSOL COMPOSITION CONTAINIG PHOMOTHEROL | 2000 |
|
RU2327452C2 |
| INHALATION PARTICLES CONTAINING COMBINATION OF ANTICHOLINERGIC, CORTICOSTEROID AND BETA-ADRENERGIC AGENTS | 2015 |
|
RU2697867C2 |
| USING FORMOTEROL AND BUDESONIDE-CONTAINING COMPOSITION FOR ACUTE ASTHMA STATE TREATMENT | 1999 |
|
RU2222332C2 |
| ORGANIC COMPOUNDS | 2001 |
|
RU2292890C2 |
